Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, has acquired PrimeFour Therapeutics’ portfolio of novel nucleoside analogs.
 
The portfolio encompasses a diverse array of unique molecular analogs. The most advanced lead compounds are nucleosides designed to exploit “synthetic lethality” in cancers with specific genetic profiles. By targeting these genetic vulnerabilities, these compounds can selectively attack susceptible cancers with reduced off-target toxicity. This approach enables personalized therapy for patients with pancreatic, certain solid tumors, and hematologic cancers that harbor newly identified genetic biomarkers.
 
“This transaction allows us to build upon our leadership in developing first-in-class and best-in-class nucleoside reverse transcriptase inhibitors for neurodegenerative and autoimmune diseases, including ALS, PSP and Alzheimer’s disease. We are excited to expand our pipeline to include this portfolio of potent nucleoside chemotherapeutics with significant therapeutic potential against a variety of cancers,” said Eckard Weber, M.D., founder and Chief Innovation Officer of Transposon. “We look forward to advancing the lead compounds into preclinical development to target DNA-damage repair deficient cancers, such as pancreatic and colorectal cancers.”

Other Pharma Industry Acquisitions